(Q46469688)

22 December 2017

title

Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma (English)

1 reference

22 December 2017

main subject

phase II clinical trial

0 references

author

Richard F. Kefford

3

1 reference

22 December 2017

Guy Toner

object named as

Guy Toner

7

0 references

author name string

Michael J Millward

1

1 reference

22 December 2017

Anthony Joshua

2

1 reference

22 December 2017

Steinar Aamdal

4

1 reference

22 December 2017

Damien Thomson

5

1 reference

22 December 2017

Peter Hersey

6

1 reference

22 December 2017

Kevin Lynch

8

1 reference

22 December 2017

publication date

1 June 2005

1 reference

22 December 2017

Investigational New Drugs

published in

1 reference

22 December 2017

volume

23

1 reference

22 December 2017

page(s)

253-256

1 reference

22 December 2017

issue

3

1 reference

22 December 2017

https://scigraph.springernature.com/pub.10.1007/s10637-005-6734-z

exact match

0 references

cites work

Methylglyoxal-bis(guanylhydrazone) (Methyl-GAG): current status and future prospects

1 reference

12 December 2020

A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.

1 reference

12 December 2020

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

1 reference

12 December 2020

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

1 reference

12 December 2020

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Gr

1 reference

12 December 2020

Treatment of nude mice with 4-amidinoindan -1- one2 '- amidinohydrazone, a new S-adenosylmethionine decarboxylase inhibitor, delays growth and inhibits metastasis of human melanoma cells

1 reference

12 December 2020

A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours.

1 reference

12 December 2020

Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies Group

1 reference

12 December 2020

CGP 48664, a new S-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity

1 reference

12 December 2020

Clinical efficacy, tolerability, and safety of SAM486A, a novel polyamine biosynthesis inhibitor, in patients with relapsed or refractory non-Hodgkin's lymphoma: results from a phase II multicenter study

1 reference

12 December 2020

Stable amplification of the S-adenosylmethionine decarboxylase gene in Chinese hamster ovary cells

1 reference

12 December 2020

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

12 December 2020

10.1007/S10637-005-6734-Z

Identifiers

DOI

1 reference

22 December 2017

PubMed ID

15868382

1 reference

22 December 2017